The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures

International Journal of Biochemistry and Cell Biology

Volumn 40, Issue 11, 2008, Pages 2492-2507

  Guay, David ^a   Evoy, Audrey Ann ^a   Paquet, Éric ^a   Garand, Chantal ^a   Bachvarova, Magdalena ^a   Bachvarov, Dimcho ^a   Lebel, Michel ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Chemoresistance; Cisplatin; Microarray; Nuclease; Splicing; YB 1

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; DOUBLE STRANDED DNA; MESSENGER RNA; MUTANT PROTEIN; NUCLEASE; OXALIPLATIN; Y BOX BINDING PROTEIN 1;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL NUCLEUS; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA REPAIR; DNA SPLICING; ENZYME ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN BINDING; UNINDEXED SEQUENCE; WILD TYPE;

ADENOVIRIDAE;

EID: 48349139331     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.04.011     Document Type: Article

References (50)

1. Bader A.G., and Vogt P.K. Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation. Mol Cell Biol 25 (2005) 2095-2106
2. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3 (1997) 447-450
3. Basaki Y., Hosoi F., Oda Y., Fotovati A., Maruyama Y., Oie S., et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26 (2007) 2736-2746
4. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57 (1995) 289-300
5. Bennett R.J., Sharp J.A., and Wang J.C. Purification and characterization of the Sgs1 DNA helicase activity of Saccharomyces cerevisiae. J Biol Chem 273 (1998) 9644-9650
6. Bergmann S., Royer-Pokora B., Fietze E., Jürchott K., Hildebrandt B., Trost D., et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 65 (2005) 4078-4087
7. Braithwaite A.W., Del Sal G., and Lu X. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Different 13 (2006) 984-993
8. Deschênes F., Massip L., Garand C., and Lebel M. In vivo misregulation of genes involved in apoptosis, development and oxidative stress in mice lacking both functional Werner syndrome protein and poly(ADP-ribose) polymerase-1. Hum Mol Genet 14 (2005) 3293-3308
9. Evdokimova V., Ovchinnikov L.P., and Sorensen P.H. Y-box binding protein 1: providing a new angle on translational regulation. Cell Cycle 5 (2006) 1143-1147
10. Fujita T., Ito K., Izumi H., Kimura M., Sano M., Nakagomi H., et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11 (2005) 8837-8844
11. Gaudreault I., Guay D., and Lebel M. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 32 (2004) 316-327
12. Gessner C., Woischwill C., Schumacher A., Liebers U., Kuhn H., Stiehl P., et al. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer. Eur Respir J 23 (2004) 14-19
13. Guay D., Gaudreault I., Massip L., and Lebel M. Formation of a nuclear complex containing the p53 tumor suppressor, YB-1, and the Werner syndrome gene product in cells treated with UV light. Int J Biochem Cell Biol 38 (2006) 1300-1313
14. Hartmuth K., Urlaub H., Vornlocher H.P., Will C.L., Gentzel M., Wilm M., et al. Protein composition of human prespliceosomes isolated by a tobramycin affinity-selection method. Proc Natl Acad Sci 99 (2002) 16719-16724
15. Hayakawa H., Uchiumi T., Fukuda T., Ashizuka M., Kohno K., Kuwano M., et al. Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 41 (2002) 12739-12744
16. Huang J., Tan P.H., Li K.B., Matsumoto K., Tsujimoto M., and Bay B.H. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol 26 (2005) 607-613
17. Ise T., Nagatani G., Imamura T., Kato K., Takano H., Nomoto M., et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 59 (1999) 342-346
18. Izumi H., Imamura T., Nagatani G., Ise T., Murakami T., Uramoto H., et al. Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and Exhibits 3′ → 5′ exonuclease activity. Nucleic Acids Res 29 (2001) 1200-1207
19. Janz M., Harbeck N., Dettmar P., Berger U., Schmidt A., Jurchott K., et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97 (2002) 278-282
20. Jurchott K., Bergmann S., Stein U., Walther W., Janz M., Manni I., et al. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 278 (2003) 27988-27996
21. Kamura T., Yahata H., Amada S., Ogawa S., Sonoda T., Kobayashi H., et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma?. Cancer 85 (1999) 2450-2454
22. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 478 (2001) 23-43
23. Kim H.J., Hwang J.Y., Kim H.J., Choi W.S., Lee J.H., Kim H.J., et al. Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin Cancer Res 13 (2007) 2577-2583
24. Kohno K., Izumi H., Uchiumi T., Ashizuka M., and Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 25 (2003) 691-698
25. Koike K., Uchiumi T., Ohga T., Toh S., Wada M., Kohno K., et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett 417 (1997) 390-394
26. Lebel M., and Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc Natl Acad Sci 95 (1998) 13097-13102
27. Levenson V.V., Davidovich I.A., and Roninson I.B. Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 60 (2000) 5027-5030
28. Liu C.-W., Corboy M.J., DeMartino G.N., and Thomas P.J. Endoproteolytic activity of the proteasome. Science 299 (2003) 408-411
29. Mehta S.A., Christopherson K.W., Bhat-Nakshatri P., Goulet Jr. R.J., Broxmeyer H.E., Kopelovich L., et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 26 (2007) 3329-3337
30. Oda Y., Ohishi Y., Saito T., Hinoshita E., Uchiumi T., Kinukawa N., et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 199 (2003) 251-258
31. Oda Y., Ohishi Y., Basaki Y., Kobayashi H., Hirakawa T., Wake N., et al. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 98 (2007) 1020-1026
32. Ohga T., Uchiumi T., Makino Y., Koike K., Wada M., Kuwano M., et al. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J Biol Chem 273 (1998) 5997-6000
33. Okamoto T., Izumi H., Imamura T., Takano H., Ise T., Uchiumi T., et al. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 19 (2000) 6194-6202
34. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19 (2002) 607-614
35. Pan Q., Shai O., Misquitta C., Zhang W., Saltzman A.L., Mohammad N., et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol Cell 16 (2004) 929-941
36. Park J.D., Nakamura H., Chumakov A.M., Said J.W., Miller C.W., Chen D.L., et al. Transactivation and DNA binding abilities of endogenous p53 mutant cell lines. Oncogene 9 (1994) 1899-1906
37. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33 (2007) 9-23
38. Raffetseder U., Frye B., Rauen T., Jurchott K., Royer H.D., Jansen P.L., et al. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J Biol Chem 278 (2003) 18241-18248
39. Rubinstein D.B., Stortchevoi A., Boosalis M., Ashfaq R., and Guillaume T. Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res 62 (2002) 4985-4991
40. Sambrook J., Fritsch E.F., and Maniatis T. Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Laboratory Press, New York (Chapter 7)
41. Schittek B., Psenner K., Sauer B., Meier F., Iftner T., and Garbe C. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance. Int J Cancer 120 (2007) 2110-2118
42. Shibahara K., Sugio K., Osaki T., Uchiumi T., Maehara Y., Kohno K., et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7 (2001) 3151-3155
43. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3 (2004) (Article 3)
44. Sorokin A.V., Selyutina A.A., Skabkin M.A., Guryanov S.G., Nazimov I.V., Richard C., et al. Proteasome-mediated cleavage of the Y-box-binding protein 1 is linked to DNA-damage stress response. EMBO J 24 (2005) 3602-3612
45. Stenina O.I., Shaneyfelt K.M., and DiCorleto P.E. Thrombin induces the release of the Y-box protein dbpB from mRNA: a mechanism of transcriptional activation. Proc Natl Acad Sci 98 (2001) 7277-7282
46. Stickeler E., Fraser S.D., Honig A., Chen A.L., Berget S.M., and Cooper T.A. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 14 (2001) 3821-3830
47. Sutherland B.W., Kucab J., Wu J., Lee C., Cheang M.C., Yorida, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24 (2005) 4281-4292
48. Swamynathan S.K., Nambiar A., and Guntaka R.V. Role of single-stranded DNA regions and Y-box proteins in transcriptional regulation of viral and cellular genes. FASEB J 12 (1998) 515-522
49. Yahata H., Kobayashi H., Kamura T., Amada S., Hirakawa T., Kohno K., et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 128 (2002) 621-626
50. Zhang Y.F., Homer C., Edwards S.J., Hananeia L., Lasham A., Royds J., et al. Nuclear localization of Y-box factor YB1 requires wild-type p53. Oncogene 22 (2003) 2782-2794